Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.
about
Components of cancer metabolism and therapeutic interventionsStructural and functional insights into Erwinia carotovora L-asparaginaseCrystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding siteEngineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutantsThe eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginaseThe glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.From Krebs to clinic: glutamine metabolism to cancer therapy.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseIdentification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing propertiesGCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase.MYC-induced cancer cell energy metabolism and therapeutic opportunities.Glutamine: an anabolic effector?L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.Asparaginase in the treatment of non-ALL hematologic malignancies.Extracellular vesicles are independent metabolic units with asparaginase activity.Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase ActivityCloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coliA clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.Asparaginase pharmacology: challenges still to be faced.Discovery of human-like L-asparaginases with potential clinical use by directed evolution.Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.Extracellular production and characterization of two streptomyces L-asparaginases.Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis.Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.L-Glutamine regulates amino acid utilization by intestinal bacteria.Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T and B cell acute lymphoblastic leukemias in vivo.Molecular dynamic simulations of Escherichia coli L-asparaginase to illuminate its role in deamination of asparagine and glutamine residues.Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase.Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children's plasma
P2860
Q26823746-EECCF304-ABA6-4E90-A23C-1D2A4EEA3768Q27651289-9DB13485-E9D8-4312-8EDF-F2B9D057BE24Q27694569-6ABE997E-1689-4500-9862-45D07CC1C217Q28543369-7292DC78-98F9-46D3-8B0F-EF6A6A89EFC5Q30497031-99865A1D-653A-4D86-927B-D6729CE5E376Q33718822-7DC8C134-C086-4D2E-AAF6-95E61C60D1A6Q33834498-EB6ECEDC-81C5-4145-A674-25A5B2ACEDF2Q34400424-B495B00D-C8B1-45C4-8337-80D094BD16C7Q34580270-D5B9CB07-CFF2-472B-A777-DFB6B928B6B4Q35086484-FE38B20B-01CC-4407-AD25-CB5E1400BA2FQ37341948-46EEAB76-C572-403E-A0A6-6CB321BF1A0CQ37432106-BBFECD30-5CF2-4C11-AB8F-2CA7F9FD7E1AQ37438881-7C9EEF73-2EEB-44A2-AEFF-D3CC06EABAB9Q37953211-F484CD11-5BAB-4964-A161-18261687E538Q38017602-44BC06CE-398B-4567-9736-D1F5FB0CBFF0Q38187018-CCEC8C56-8903-4FAB-8CA9-FCD4A643504AQ38696824-D3E33403-3A15-44D6-AC42-85DBE16733F7Q38761096-8436F82B-6045-4F09-9CD9-6AC55FF9DC58Q38782564-8F86972C-E96F-4D3B-8B4E-117D00CD7067Q38838632-63D69686-9965-422F-B593-F7B2B8F57FD8Q38970692-65047F89-937D-4222-9F06-D2FAC0ADBA3FQ38994917-0B6821DF-B707-4C8E-9711-2E5BDE93BB9EQ39135887-2049BD0B-31F1-4719-991F-79BEA5AC276AQ41581505-6F8364D2-1FE9-4ED1-82FA-737D929570D3Q41899682-90AD027F-468C-4743-B665-0A072C862EE0Q43029494-301167EA-A35E-4C75-B18D-C8A5FCCFADE4Q43765047-7CB2AB5C-12AC-4A56-9C27-DF59311B23D4Q44151227-D9F59E4F-0E90-4EB6-8F7C-8ACA89548482Q44447298-2B26993D-2C2D-4C9B-A038-0494853A58A8Q46518378-6AEBC651-035C-4213-8454-16B06583932EQ49032263-A4F1B3A5-9BF4-4A59-AF9E-07426C397284Q53348077-469AF25C-37F6-46DF-9449-DC4B54DDD859Q54457075-546757F8-436A-4799-B2AD-F1708FA862DDQ58563335-57DAA348-DFE0-42E2-A5D8-03FD7E747FAC
P2860
Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@en
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@nl
type
label
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@en
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@nl
prefLabel
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@en
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@nl
P2093
P2860
P1476
Asparaginase-induced derangeme ...... ome drug-related side-effects.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2362.1988.TB01049.X
P577
1988-10-01T00:00:00Z